Our human skin S9 fraction is prepared from ethically sourced, non-diseased human skin tissue and contains both microsomal and cytosolic enzymes, providing a comprehensive in vitro system for evaluating dermal drug metabolism. This fraction is particularly well-suited for studies involving prodrug activation, detoxification, and enzyme-mediated skin toxicity.
The S9 fraction retains carboxylesterases and oxidoreductases, allowing for broad metabolic profiling of topically applied pharmaceuticals, cosmetics, and environmental chemicals. Each batch is processed under cold conditions to preserve enzymatic activity and ensure consistent performance in safety and efficacy testing.